Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01489345 · ClinicalTrials.gov registry record · Phase 1

Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects

A Phase 1 study of Healthy, sponsored by Ono Pharma USA.

Completed
Registry status
Phase 1
Development phase
36
Enrollment target
1
Study location

NCT01489345: Completed Phase 1 study of Healthy, sponsored by Ono Pharma USA.

NCT01489345 is a Phase 1 study of Healthy that has completed, run by Ono Pharma USA. The registered enrollment target is 36 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01489345, a Phase 1 study of Healthy, has completed, sponsored by Ono Pharma USA.

COMPLETED
Registry status
Phase 1
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

The primary objective of this study is to evaluate the safety and tolerability of ONO-2952 across ascending multiple doses in healthy adult male and female subjects. The secondary objective is to characterize the pharmacokinetic (PK) profile of ONO-2952.

Conditions Studied

Interventions

  • DRUG ONO-2952
  • DRUG ONO-2952 Matching Placebo

Study Locations (1)

Texas

  • Austin Clinical Site - Austin

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2011-12
Phase Phase 1
Ono Pharma USA

17 total trials

What the finished NCT01489345 record still lists

NCT01489345 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which ONO-2952 is the first listed.

NCT01489345 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT01489345 about?

NCT01489345 is a clinical study titled "Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects". The primary objective of this study is to evaluate the safety and tolerability of ONO-2952 across ascending multiple doses in healthy adult male and female subjects. The secondary objective is to characterize the pharmacokinetic (PK) profile of ONO-2952.

What is the current status of trial NCT01489345?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2011-12.

What conditions does trial NCT01489345 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT01489345?

The interventions under investigation include: ONO-2952 (DRUG), ONO-2952 Matching Placebo (DRUG).

Who is sponsoring clinical trial NCT01489345?

This trial is sponsored by Ono Pharma USA, which has 17 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01489345 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01489345's enrollment target sits among peer trials

36 595th of 1090 higher than 469 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00929006 · 36 participants · Early Phase 1

    Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

  • NCT01891318 · 36 participants · Phase 1

    Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

  • NCT02291848 · 36 participants · Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

  • NCT02366819 · 36 participants · Phase 4

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01489345, the US trial registry maintained by the National Library of Medicine. NCT01489345 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.